Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 54Temozolomide 50Filgrastim 25Cyclophosphamide 25Etoposide 24Cisplatin 22Carboplatin 22Vincristine 19Chemotherapy, Adjuvant 18Peripheral Blood Stem Cell Transplantation 15Thiotepa 13Carmustine 12Thalidomide 10Methotrexate 9Magnetic Resonance Spectroscopy 9Irinotecan 9Bevacizumab 9Granulocyte Colony-Stimulating Factor 7sargramostim 6Topotecan 6Lomustine 6X-Rays 5Tamoxifen 5Specimen Handling 5Phantoms, Imaging 5O(6)-benzylguanine 5Ifosfamide 5Erlotinib Hydrochloride 5Drug Therapy 5Celecoxib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Central Nervous System Neoplasms × CT-322 × Clear all
NCT00562419 2010-10-27

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 2 Unknown
72 enrolled
CNS

Glioblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡